Electroconvulsive Therapy for Parkinson’s Disease with Depression and Neuroleptic Malignant Syndrome: A Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Parkinson’s disease is often complicated by psychiatric symptoms. Psychiatrists are caught in a dilemma between such symptoms and physical treatment since Parkinson’s disease sometimes shows treatment resistance based on pharmacological treatment-induced dopamine dysfunction. Here, we report on a 64-year-old woman with a 15-year history of Parkinson’s disease with stage IV severity based on the Hoehn and Yahr scale. She was admitted to our hospital with a diagnosis of major depressive disorder with psychotic features. Unfortunately, her treatment course for depression was complicated by neuroleptic malignant syndrome. Because we were concerned about the persistence of her depressive symptoms, the risk of psychotropic drugs causing adverse effects, and progressive disuse syndrome, we administered modified electroconvulsive therapy. Her symptoms of neuroleptic malignant syndrome and depression sufficiently improved after five sessions of modified electroconvulsive therapy. Additionally, the primary motor symptoms of her Parkinson’s disease also markedly improved. The improvement of neuroleptic malignant syndrome and her motor symptoms based on dopamine dysfunction can be explained by electroconvulsive therapy’s effectiveness in activating dopamine neurotransmission. Besides, the marked improvement of her depressive episode with psychotic features was presumed to involve dopamine receptor activation and regulation. Because advanced Parkinson’s disease can sometimes be refractory to treatment based on pharmacological treatment-induced dopamine dysfunction, psychiatrists often have difficulty treating psychiatric symptoms; electroconvulsive therapy may stabilize the dopaminergic system in such cases, presenting a possible non-pharmacologic treatment option for Parkinson’s disease.
Abstract
Parkinson’s disease is often complicated by psychiatric symptoms. Psychiatrists are caught in a dilemma between such symptoms and physical treatment since Parkinson’s disease sometimes shows treatment resistance based on pharmacological treatment-induced dopamine dysfunction. Here, we report on a 64-year-old woman with a 15-year history of Parkinson’s disease with stage IV severity based on the Hoehn and Yahr scale. She was admitted to our hospital with a diagnosis of major depressive disorder with psychotic features. Unfortunately, her treatment course for depression was complicated by neuroleptic malignant syndrome. Because we were concerned about the persistence of her depressive symptoms, the risk of psychotropic drugs causing adverse effects, and progressive disuse syndrome, we administered modified electroconvulsive therapy. Her symptoms of neuroleptic malignant syndrome and depression sufficiently improved after five sessions of modified electroconvulsive therapy. Additionally, the primary motor symptoms of her Parkinson’s disease also markedly improved. The improvement of neuroleptic malignant syndrome and her motor symptoms based on dopamine dysfunction can be explained by electroconvulsive therapy’s effectiveness in activating dopamine neurotransmission. Besides, the marked improvement of her depressive episode with psychotic features was presumed to involve dopamine receptor activation and regulation. Because advanced Parkinson’s disease can sometimes be refractory to treatment based on pharmacological treatment-induced dopamine dysfunction, psychiatrists often have difficulty treating psychiatric symptoms; electroconvulsive therapy may stabilize the dopaminergic system in such cases, presenting a possible non-pharmacologic treatment option for Parkinson’s disease.
참고문헌 (13)
- Levenson JL, "Neuroleptic malignant syndrome", Am J Psychiatry, 142, pp.1137~1145 (1985)
- Pope HG Jr, "Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital", Am J Psychiatry, 143, pp.1227~1233 (1986)
- Velamoor R, "Neuroleptic malignant syndrome : a neuro-psychiatric emergency : recognition, prevention, and management", Asian J Psychiatr, 29, pp.106~109 (2017)
- Gortney JS, "Neuroleptic malignant syndrome secondary to quetiapine", Ann Pharmacother, 43, pp.785~791 (2009)
- Haddow AM, "Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin", BMJ, 329, pp.1333~1335 (2004)
- Nisijima K, "A rare case of neuroleptic malignant syndrome without elevated serum creatine kinase", Neuropsychiatr Dis Treat, 10, pp.403~407 (2014)
- Cumper SK, "Electroconvulsive therapy(ECT)in Parkinson’s disease : ECS and dopamine enhancement", J ECT, 30, pp.122~124 (2014)
- Breuer ME, "Antidepressant effects of pramipexole, a dopamine D3", D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats, 2009, pp.616, 134~140
- Vriend C, "Depression and impulse control disorders in Parkinson’s disease: two sides of the same coin?", Neurosci Biobehav Rev, 38, pp.60~71 (2014)
- FP-CIT binding in the caudate nucleus, "J Neurol Neurosurg Psychiatry", 2014, 159~164
- Cooper SJ, "The effect of electroconvulsive therapy on CSF amine metabolites in schizophrenic patients", Br J Psychiatry, 152, pp.59~63 (1988)
- Baldinger P, "Neurotransmitters and electroconvulsive therapy", J ECT, 30, pp.116~121 (2014)
- Amit Singh, "How Electroconvulsive Therapy Works?: Understanding the Neurobiological Mechanisms", Clinical Psychopharmacology and Neuroscience, 15(3), pp.210~221 (2017), 대한정신약물학회[DOI]